Clinical Trials Browser

Phase 2 × larotrectinib × Plasma cell × Clear all

NCT06390852 2025-11-04

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Phase 2 Active not recruiting

LymphoidPlasma cell

Lymphoma, Multiple Myeloma